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HIV Prevalence and Incidence 
United States, 1980 - 2010 
Number of people living with HIV has grown because  
incidence is relatively stable and survival has increased 
Hall HI et al. JAMA. 2008 Aug 6;300(5):520-9 
Prejean J et al. PLoS One. 2011;6(8):e17502 






 African Americans are 8 times more likely and  
     Latinos are 3 times more likely to have HIV than whites 
 Inequities in lifetime risk for HIV diagnosis among women 
 1 in 139 for all women  
 1 in 32 African American women 
 1 in 106 Latino women  
 1 in 182 Native Hawaiian/Pacific Islander women  
 1 in 217 American Indian/Alaska Native women  
 1 in 526 white or Asian women 
 HIV prevalence is associated with population density, region 
of residence, poverty, education, employment, and 
homelessness 
 Men who have sex with men (MSM) are >40 times  
more likely to have HIV than other men 
 
CDC, HIV Surveillance Report, 2009; ww.cdc.gov/hiv/surveillance/resources/reports  
Purcell, National STD Prevention Conference, 2010 
Denning, International AIDS Society, 2010 
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Lifetime Risk of HIV Infection among MSM 
Stall R et al. AIDS Behav. 2009 Aug;13(4):615-29  




























If current trends continue, half 
of today’s young black MSM 
will have HIV by age 35 
Half of all MSM will have  
HIV by age 50 
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Faster Action Now  
Saves Lives and Resources Later 
Adapted from : 
Hall HI et al. J Acquir Immune Defic Syndr. 2010 Oct;55(2):271-6 
 
      Stable Incidence: 550,000 additional cases in 10 years 
     Reducing incidence by 25%  
 In 10 years would save 62,000 infections and $23 billion  


















25% reduction in 10 years

















Prevention with HIV(+) Persons  
 HIV testing, linkage to care and 
prevention services 
 Antiretroviral therapy 
 Retention in care and adherence 
 Partner services 
 Behavioral risk reduction 
interventions and condoms 
 STD screening and treatment 
 Perinatal transmission interventions 
Prevention Not Focused on HIV Status 
 Social mobilization 
 Condom availability 
 Substance use, mental health, and social support 
Prevention with HIV (-) Persons 
 Condom distribution 
 Behavioral risk reduction  
interventions and condoms 
 Pre-exposure prophylaxis (PrEP) 
 Post-exposure prophylaxis 
 Syringe services 
 Male circumcision 
 Microbicides 
 STD screening and treatment 




Multiple Disciplines and Approaches 
Adapted from : 
Coates TJ, Richter L, Caceres C. Lancet. 2008 Aug 23;372(9639):669-84 
Combining 
interventions  

















are not equal 







Establish cost and cost 
effectiveness per  
infections averted  
and life-years saved  
Determine 
















All diagnosed persons 
MMWR 2011 Dec 2;60(47):1618-23 
ART, Antiretroviral therapy 
Prescribed ART 
Any HIV care 
All persons with HIV 
All people with  
All diagnosed persons 
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Regular HIV care 
PUBLIC HEALTH  
CLINICAL  
MEDICINE 
High-Impact Prevention (HIP) 
Clinical Medicine and Public Health  
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Viral Load Suppression 
All diagnosed persons 
Prescribed  ART 
Any HIV care 
All persons with HIV 
Hall I, XIX International AIDS Conference, 2012 
ART, Antiretroviral therapy 
All people with  
All diagnosed persons 
 Any HIV care 
Suppressed 
viral load  
  
Regular HIV care 
25% 
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 Public health responsibility to close gaps in HIV 
care and prevention services 
 At individual level, lower viral load reduces morbidity and 
mortality, and reduces chance of spreading HIV 
 Population level, viral load leads to fewer new infections  
 Emulate successful programs in other  
    disease areas 
 Example: Hemoglobin A1C registry and diabetes monitoring in 
New York City 
 
 
Strengthening the Public Health Approach to HIV 
13 
Success in San Francisco 
Community Viral Load and HIV Incidence 
 
Das M et al. PLoS One. 2010 Jun 10;5(6):e11068 
CVL, Community viral load 
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 $339 million annually, allocated based on HIV prevalence 
 Allows flexibility based on local epidemic modeling and needs 
 Focuses on interventions that will have greatest impact on epidemic 
with 75% of budget focused on 4 key strategies: HIV testing, prevention 
with positives including ART, policy, and condom distribution 
Aligning Resources with the Epidemic 
CDC Funding of State and Local Health Departments 
Proportion of Americans Diagnosed with HIV Who Live in Each State (2008) Proportion of CDC Core HIV Prevention Funding—FY20162  
www.cdc.gov/hiv/strategy/hihp/healthDepartments/ 
15 
  Expanded Testing Initiative 
 2.8 million tests conducted in first 3 years 
 18,000 people newly diagnosed with HIV 
 70% African American and 12% Latino 
 Averted an estimated 3,400 HIV infections 
 Achieved a return of $1.97 for every dollar invested 
 Care and Prevention demonstration projects  
 $14.5 million annually over 3 years for 6 - 9 states 
 Monitor and improve diagnosis, linkage, retention, ART provision, 
viral suppression, and behavioral prevention by using individual and 
community-level surveillance data 
 Provide information to patients and clinicians to improve outcomes 
 
CDC is Implementing the Principles of  
High-Impact Prevention 
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 Growing number of people with HIV and restricted 
budget require higher impact strategies 
Window for success may be closing, requiring 
swift action 
 Large disparities require conscious application of 
health equity approaches 
 Public health prevention, care, and surveillance 
programs must be integrated 
Conclusions 
17 
New Directions in Monitoring the Burden of HIV  
Irene Hall, PhD, MPH, FACE 
Division of HIV/AIDS Prevention 
Centers for Disease Control and Prevention 
HIV Surveillance In Action  
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All people with  
All diagnosed persons 




HIV Case Surveillance 
Data for Prevention 
 Sources of reports 
 Hospital practitioners 
 Private practitioners 
 Public clinics 
 Laboratories 
People with HIV 
POPULATION 
HEALTH  
All persons with HIV 
Any HIV care 
Regular HIV care 
All diagnosed persons 
 Surveillance then 
 Few sentinel events 
 Surveillance now 
 Continuous data collection 
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National HIV/AIDS Strategy  
Primary Goals 
 Reduce the number of people who become 
infected with HIV 
 Increase access to care and optimize health 
outcomes for people living with HIV 
 Reduce HIV-related health disparities 
 
 The White House Office of National AIDS Policy. Washington D.C.: White House, July 13, 2010 
www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf 
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National HIV/AIDS Strategy  
Indicators of Need and Outcome for Prevention Efforts 
 Incidence 
 Prevalence, including undiagnosed persons 
 Persons unaware of their infection disproportionately transmit HIV 
 Identifying them for targeted testing: first step in prevention efforts 
 Transmission rate 
 Annual number of new infections per 100 persons living with HIV 
 Linkage to care  
 Retention in care 
 Viral suppression 
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HIV Surveillance: Incidence 
 First incidence estimates released in 2008 
 First 4-year trend released in 2011 
 Persons diagnosed with HIV may have been infected  
for many years  
 Laboratory assays can distinguish recent from  
long-term infections at the population level 
 Incidence estimates are based on the number of recent 
infections and additional information on testing among 
persons diagnosed with HIV 
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Estimated HIV Incidence Rates, by Race/Ethnicity 
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Rate per 100,000 
Prejean, J et al. PLoS ONE 6(8): e17502 
Annual U.S. incidence:               ~ 50,000 cases 
2009 U.S. incidence rate:                  9.0/100,000 
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HIV Infection Diagnosis Rates 
Among Adults and Adolescents, 2010 
 
46 States and 5 U.S. Dependent Areas, N=48,079 
Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis 



















































































































































No. living with undiagnosed HIV infection
No. living with diagnosed HIV infection
Transmission rate
Adults and Adolescents Living with HIV Infection 
and HIV Transmission Rate, United States 
MMWR 2012;61(Suppl; June 15, 2012):57-64 
Holtgrave et al. J Acquir Immune Defic Syndr 2009;50(2):236-38 

















Persons with HIV Engaged in Selected Stages 













Hall et al. XIX International AIDS Conference, 2012 
ART, Antiretroviral therapy 
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 Aggregate data can be used on various  
    geographic levels for   
 Prevention planning 
 Resource allocation 
 Outcome evaluation  
Public Health in Action: Aggregate Data  
27 
Public Health in Action: Individual Data 
 Individual level data help determine whether people 
are in care and/or have a suppressed viral load 
 This information can be used  
To alert providers to engage or re-engage people in care or  
By the health department to contact patients directly in order to 
assure they receive the services they need 
 
Maintaining personally identifiable data and these 
follow-up activities require careful planning 
 Protocols for confidential data sharing 





 Data indicate targets for high-impact prevention 
 Data allow monitoring of key outcome indicators  
of the National HIV/AIDS Strategy 
Surveillance has become  
a continuous data collection system  
that can provide data for public health action  
 on provider and individual level 
29 
Modeling to Identify Optimal Allocation of HIV 
Prevention Resources in a City Health Department 
Stephanie L Sansom, PhD, MPP, MPH 
Division of HIV/AIDS Prevention 
Centers for Disease Control and Prevention 
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The Value of Modeling  
Modeling of resource allocation helps state and local 
health departments 
 Divide scarce prevention dollars among programs  
and population 
 Achieve the most impact at least cost 
 Identify high-impact prevention strategies 
31 
CDC - Philadelphia Collaboration 
2011–2012 
Model optimal combination of HIV prevention 
programs to address city’s HIV epidemic  
 Develop a tool other local jurisdictions might use 
 
32 
 HIV resource allocation model 
 Projects new HIV cases for 1-–5 years   
  Estimates best allocation of HIV prevention budget 
Among programs and populations  
To prevent most HIV cases 
 Incorporates 
HIV prevention budget: $12 million 
Size and characteristics of populations with or at risk for HIV 
Percent of risk population reachable 
Prevention intervention characteristics 
 Cost, efficacy, and duration of effect 
Methods 
33 
 Calculate reduced likelihood of HIV infection 
following prevention intervention 
 Number of and type of HIV exposures 
Unprotected sex and needle sharing 
 HIV prevalence among partners 
 HIV transmission probability per exposure 
 Efficacy of intervention in preventing HIV 
 Calculate cost of intervention per infection averted  




CDC criteria: Inclusion of interventions that are 
 Aligned with principles of high-impact HIV prevention 
 Required in CDC-funded cities with high HIV prevalence  
 Targeted to populations with greatest number of new infections 
 Supported by scientific evidence on infection rate reduction 
Methods 
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Prevention with HIV(+) Persons  
 HIV testing, linkage to care and 
prevention services 
 Antiretroviral therapy 
 Retention in care and adherence 
 Partner services 
 Behavioral risk reduction 
interventions and condoms 
 STD screening and treatment 
 Perinatal transmission interventions 
Prevention Not Focused on HIV Status 
 Social mobilization 
 Condom availability 
 Substance use, mental health, and social support 
Prevention with HIV (-) Persons 
 Condom distribution 
 Behavioral risk reduction  
interventions and condoms 
 Pre-exposure prophylaxis (PrEP) 
 Post-exposure prophylaxis 
 Syringe services 
 Male circumcision 
 Microbicides 
 STD screening and treatment 
Not all interventions are supported financially by CDC or other federal agencies 
36 
Philadelphia HIV Community Profile  
* New HIV diagnoses in Philadelphia in 2009 
& PLWH, People living with HIV, undiagnosed and diagnosed in Philadelphia in 2009  












     340    (37)  8,528   (35)     245,208   (76) 
Intravenous 
drug users  
     136    (15)        7,175   (30)     41,001   (13) 
Men who have 
sex with men 
  433    (48)        8,356   (35)    37,882   (12) 
Total      909  (100) 
  24,060 (100) 
  
 324,091 (100) 
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Untargeted interventions  Cost per new infection averted (rank) 
  Testing in clinical settings     51,293  (3)  
  Partner services      99,105  (7)  
  Linkage to care    114,644  (8)  
  Retention in care     75,665  (5)  
  Adherence to ART     42,753  (2) 
Targeted interventions HRH IDU MSM 
Testing in non-clinical settings 866,272  (12)   53,935    (4)    17,965  (1)  
Behavioral intervention for HIV+ 
people 
594,796  (10)  700,005  (11)    97,410  (6)  
Behavioral intervention for HIV- 
people 
15,642,127  (14)  2,931,406  (13)  327,210  (9)  
Cost per Infection Averted ($) 
ART, Antiretroviral therapy 
HRH, High risk heterosexuals 
IDU, Injection drug users  
MSM, Men who have sex with men  
38 
Optimal Allocation: $12 Million Budget  
Untargeted interventions Budget (%) 
  Testing in clinical settings    39  
  Partner services       
  Linkage to care       
  Retention in care     32 
  Adherence to ART       7  
  Targeted interventions HRH IDU MSM 
  Testing in non-clinical settings 13 8 
  Behavioral intervention for HIV+ people   
  Behavioral intervention for HIV- people   
  Total 
ART, Anti retroviral therapy 
HRH, High risk heterosexuals 
IDU, Injection drug users  
MSM, Men who have sex with men  
39 
Optimal Allocation: $25 Million Budget 
Untargeted interventions Budget (%) 
  Testing in clinical settings    19  
  Partner services    19 
  Linkage to care     16 
  Retention in care     32  
  Adherence to ART       3  
  Targeted interventions HRH IDU MSM 
  Testing in non-clinical settings 6 4 
  Behavioral intervention for HIV+ people 2  3 
  Behavioral intervention for HIV- people   11 
  Total 
ART, Anti retroviral therapy 
HRH, High risk heterosexuals 
IDU, Injection drug users  
MSM, Men who have sex with men  
40 
Optimal Allocation: $50 Million Budget 
Untargeted interventions Budget (%) 
  Testing in clinical settings    10  
  Partner services      9 
  Linkage to care      8 
  Retention in care      9  
  Adherence to ART       2  
  Targeted interventions HRH IDU MSM 
  Testing in non-clinical settings 16 3 2 
  Behavioral intervention for HIV+ people 2  1 2 
  Behavioral intervention for HIV- people  7 6 5 
  Total 
ART, Anti retroviral therapy 
HRH, High risk heterosexuals 
IDU, Injection drug users  
MSM, Men who have sex with men  
41 
HIV Infections Averted 
by Budget Amount 
 $12  
 $25  
 $50  
 74  
 121  

























Total HIV prevention budget (in millions $)          
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 Philadelphia has used CDC model to inform  
funding decisions 
 More screening of  MSM in non-clinical settings 
 More behavior change programs for positives, especially MSM 
 Fewer behavior change programs for negatives, none for 
heterosexuals 
CDC - Philadelphia Collaboration 
2011–2012 
MSM, Men who have sex with men  
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Limitations of Modeling 
Models often rely on uncertain data  
    and assumptions 
 Critical to conduct sensitivity analyses  
 Validate projected outcomes against empirical data  
Models may not incorporate important elements 
 Equity 
 Political or practical barriers to implementation 
 Synergies among prevention interventions 
 
44 
Advantages of Modeling 
Modeling can  
 Synthesize data from many sources (including local data) 
 Summarize complex issues in a transparent way 
 Serve as a methodology for comparing interventions 
 Illuminate planning and programmatic decisions 
 CDC continues to refine models to help support 
planning of local HIV prevention 
 
45 
Grant Colfax, MD 
Office of National AIDS Policy 
The White House 
 
 
Overview of the National HIV/AIDS Strategy 
Implementation 
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National HIV/AIDS Strategy  
2015 Health Targets 
 Reducing new infections 
 Lower annual number of new infections by 25% 
 Reduce transmission rate by 30% 
 Increase from 79% to 90% the percentage of people living with HIV 
who know their status 
 Increasing access to care and improving health 
outcomes 
 Increase the proportion of newly diagnosed patients linked to care 
within 3 months of diagnosis from 65% to 85% 
 Increase proportion of Ryan White clients who are engaged in care 
from 73% to 80% 
 Increase number of Ryan White clients with permanent housing 
from 82% to 86% 
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National HIV/AIDS Strategy  
2015 Health Targets 
 Reducing HIV-related health disparities and  
    health inequities 
 Increase the proportion of diagnosed gay and bisexual men with 
undetectable viral load by 20% 
 Increase the proportion of Black Americans with  
    undetectable viral load by 20% 
 Increase the proportion of Latinos with  




President Obama’s 2013 HIV Budget  
 $22.3 billion for domestic HIV-related activities 
 $963 million increase over 2012 
 $1 billion for AIDS Drug Assistance Programs 
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Reaching NHAS Goals 
 Prioritize health outcomes 
 A few key metrics 
 Smarter investments 
 Target populations 
 Evidence-based interventions 
 Shared responsibility 
 Federal, State, local, non-profit and corporate partners 
 Accountability 
 Scale up what’s working 
 Change what’s not 
 Emphasize effectiveness and cost savings  
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Aligning Resources with the Epidemic 
www.cdc.gov/hiv/strategy/hihp/healthDepartments/ 
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 Optimal combination of interventions? 
 Metrics to measure local program success? 
 Resources used by populations at greatest risk? 




CDC’s High-Impact Prevention:  
Ground Level Implementation of NHAS 
NHAS, National HIV/AIDS Strategy 
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HIV Treatment: a Win-Win-Win 
 Earlier treatment improves health: HHS and IAS 
guidelines now recommend starting treatment 
regardless of immune status 
 Treatment is prevention: reduction in transmission 
risk to partners 96% 
 Treatment is cost effective  
 
Cohen MS et al, N Engl J Med. 2011 Aug 11;365(6):493-505 
Thompson MA et al, JAMA. 2012 Jul 25;308(4):387-402 
DHHS HIV-1 Treatment Guidelines 2012; www.aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf  
53 
Increasing HIV Testing and Treatment to  
Achieve the Strategy’s Goals 
Sorensen SW et al, PLoS One 2012;7(2):e29098. 
NHAS, National HIV/AIDS Strategy  
























HIV and Health Coverage 
 Of U.S. PLWHA,       
 approximately:  
 13% have  
    private coverage 
 24% have no coverage 
 47% receive Medicaid  
 Over 500,000 receive 
some form of  
   Ryan White services 
HRSA, http://www.healthcare.gov 
Kaiser Family Foundation; aidsvu.org 
PLWHA, Persons living with HIV/AIDS 
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HIV-related Disparities and Healthcare 
HIV health outcome 
disparities in: 
 Time To AIDS and death 
after AIDS diagnosis, for 
black and Latino MSM 
relative to white MSM  
 Excess deaths, for blacks 
compared to whites 
 Life expectancy losses, for 
Latinos compared to blacks 
or whites  
 Life expectancy losses, for 
Latina and black women       
compared to white women 
BUT: No difference in time to 
AIDS or mortality by race  
in HMO system 
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Silverberg et al, J Gen Intern Med. 2009 July 16;24(9): 1066-72  
Hall et al, Am J Public Health. 2007 Jun;97(6):1060-6 
Levine RS et al, Am J Public Health. 2010 Nov;100(11):2176-84 
Losina E et al, Clin Infect Dis. 2009 Nov 15;49(10):1570-8 
HMO, Health Maintenance Organization  
 
 
HR (95% CI) P 
White 1 
Black 1.2 (0.9-1.5) 0.25 
Hispanic 0.8 (0.6-1.1) 0.17 
HR (95% CI) P 
White 1 
Black 1.1 (0.9-1.4) 0.27 
Hispanic 0.7 (0.5-0.9) 0.01 
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Toward Health Equity: The Affordable Care Act 
 Expands coverage to 30 million Americans 
 Tens of thousands with HIV 
 Millions of blacks and Latinos 
 Prohibits denials of coverage based on HIV status 
 Already: 
 Millions have increased  
prevention service coverage 
 Millions of young adults  
covered on parents’ plans 
 Coverage necessary but not sufficient  
to improve HIV outcomes 
 Continued need to address stigma, discrimination, 
     and barriers to access and engagement in care 
Office of the Assistant Secretary for Planning and Evaluation, 2012  
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Measuring HIV-related Outcomes:  









Ongoing NHAS Implementation Needs 
 Continued collaboration among Federal, State, local 
government, and private partners   
 Flexibility at local level while maintaining alignment 
with NHAS principles 
 Technical assistance to prepare HIV workforce for 
ongoing changes in environment 
 Shift from process-oriented to outcome-oriented 
metrics 
 Prioritize maximizing the continuum of care   
 Research to determine best ways to move forward 
among multiple options 
 Support ongoing basic and clinical research 
NHAS, National HIV/AIDS Strategy 
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NHAS implementation update report:   
aids.gov/federal-resources/national-hiv-aids-strategy/implementation-update-2012.pdf 
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